Androgen deprivation therapy is linked to more acute kidney injury

Design

Systematic review and meta-analysis of observational studies

Population

72,980 patients with prostate cancer, on or off androgen deprivation therapy

Primary outcome

Acute kidney injury

Effect

Odds ratio 1.34 (95% CI 1.29-1.40); GnRH agonists 1.49 (1.02-2.17)

Androgen deprivation therapy is a mainstay of prostate cancer treatment, but its renal effects get little attention. This meta-analysis pooled four observational studies, 72,980 patients, comparing those on androgen deprivation therapy with those not.

Androgen deprivation therapy was associated with higher odds of acute kidney injury (odds ratio 1.34, 95% CI 1.29 to 1.40). The signal was clearest for GnRH agonists (odds ratio 1.49), while surgical orchiectomy was not significantly associated with AKI, and orchiectomy carried a lower AKI rate than GnRH agonist therapy. The evidence is observational, so confounding by the cancer and its comorbidities cannot be excluded.

The practical change is to fold kidney protection into prostate cancer care: check renal function before and during androgen deprivation therapy, avoid stacking nephrotoxins and maintain hydration around imaging and procedures, and weigh the AKI signal when choosing between modalities in a patient already at renal risk.

• Meta-analysis of four observational studies, 72,980 prostate cancer patients.
• Androgen deprivation therapy was associated with higher AKI odds (odds ratio 1.34).
• The association was clearest for GnRH agonists (odds ratio 1.49).
• Orchiectomy was not significantly associated with AKI.
• Monitor renal function and avoid stacking nephrotoxins during therapy.

Why it matters

It puts acute kidney injury on the radar for a very commonly used therapy where renal monitoring is often overlooked.

Don't overread it

The evidence is observational, so it shows association rather than cause; the cancer and its comorbidities may contribute to the AKI signal.

The statistics, in plain English

An odds ratio of 1.34 is a modest relative increase, and the subgroup difference between GnRH agonists and orchiectomy could reflect who receives each rather than a direct drug effect. The tight confidence interval partly reflects large numbers, not freedom from confounding.

Read the rest in the app

You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.

Get Daily Doctor — free

Scan to keep reading on your phone. No account needed to start.